Small molecule · developed by Nektar Therapeutics
NKTR-181 is an orally administered tablet studied in osteoarthritis of the knee, low back pain, and chronic pain.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02367820 | Phase 3 | Low Back Pain | Completed | NKTR |
| NCT01619839 | Phase 2 | Osteoarthritis of the Knee | Completed | NKTR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic PainLow Back PainOsteoarthritis of the Knee
Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.
See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NKTR catalysts and pipeline →